2353 Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma. (September 2015) - Qin, S.; Lim, H.Y.; Ryoo, B.Y.; Li, C.; Xiong, H.; Ihling, C.; Cheng, A.L.